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Functional gastrointestinal disorders (FGIDs) are diagnosed and classified using the Rome criteria; the criteria may change over time 
as new scientific data emerge. The Rome IV was released in May 2016. The aim is to review the main changes in Rome IV. FGIDs 
are now called disorders of gut-brain interaction (DGBI). Rome IV has a multicultural rather than a Western-culture focus. There 
are new chapters including multicultural, age-gender-women’s health, intestinal microenvironment, biopsychosocial, and centrally 
mediated disorders. New disorders have been included although not truly FGIDs, but fit the new definition of DGBI including opioid-
induced gastrointestinal hyperalgesia, opioid-induced constipation, and cannabinoid hyperemesis. Also, new FGIDs based on available 
evidence including reflux hypersensitivity and centrally mediated abdominal pain syndrome. Using a normative survey to determine the 
frequency of normal bowel symptoms in the general population changes in the time frame for diagnosis were introduced. For irritable 
bowel syndrome (IBS) only pain is required and discomfort was eliminated because it is non-specific, having different meanings in 
different languages. Pain is now related to bowel movements rather than just improving with bowel movements (ie, can get worse 
with bowel movement). Functional bowel disorders (functional diarrhea, functional constipation, IBS with predominant diarrhea 
[IBS-D], IBS with predominant constipation [IBS-C], and IBS with mixed bowel habits) are considered to be on a continuum rather 
than as independent entities. Clinical applications such as diagnostic algorithms and the Multidimensional Clinical Profile have been 
updated. The new Rome IV iteration is evidence-based, multicultural oriented and with clinical applications. As new evidence become 
available, future updates are expected.
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Introduction  
Functional gastrointestinal disorders (FGIDs) classification 
and diagnostic criteria began in the late 1980s, when a group of 
international experts were recruited by Professor Aldo Torsoli from 
Italy to develop Working Teams for the International Gastroenter-
ology meeting in Rome 1988. The purpose was to answer difficult 
questions using a consensus methodology through the Delphi ap-
proach about a group of gastrointestinal disorders that had little sci-
entific-based evidence to understand etiology pathophysiology and 
treatment at the time. One committee was established to develop 
for the first time diagnostic guidelines for irritable bowel syndrome 
(IBS). This was chaired by Prof W Grant Thompson from Canada 
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and published in 1989.1,2 This IBS Working Team was the starting 
point for the Rome process that later generated consensus-based 
criteria for other disorders without an anatomical or structural basis. 
With the support of Dr Enrico Corazziari representing Dr Aldo 
Torsoli, Dr Douglas A Drossman, a member of the original IBS 
Working Team, set up another working team to create a classifica-
tion system with diagnostic criteria for all of the FGIDs. The classi-
fication was divided into 5 anatomical regions including the esopha-
gus, gastroduodenal tract, bowel, biliary tract, and anorectal area, 
and was published in Gastroenterology International.3 A refinement 
of the classification system was made with a series of papers in the 
same journal by 5 additional working teams.3-7 In all, there were 
criteria for 21 FGIDs and this led to the development of a research 
instrument to conduct an epidemiological survey used for the first 
US Householder Epidemiological Study,8 a seminal paper in the 
field. These papers were further compiled in a book entitled “The 
functional gastrointestinal disorders: diagnosis, pathophysiology 
and treatment,” published in 1994.9
The birth of the Rome process and its classification system 
served as the basis for an incredible explosion of research in the field 
as well as to legitimize the patient’s having these symptoms.10 How-
ever, with evolving science and new evidence, the Rome process 
became a dynamic one requiring updates leading to revisions in the 
publications. Therefore, 28 years after the first Working Team on 
IBS, and 10 years after the last iteration of the Rome process (Rome 
III) were published, the Rome IV process and consequently the 
modified Rome IV classification and criteria have been published in 
a supplement of Gastroenterology as well as in a collection of books, 
both in hard copies and online, this past May 2016.11,12
This was accomplished by a rigorous process of prospective 
and retrospective data collection, synthesis, data discussion, group 
decision making, and peer-review.13 Table 1 summarizes the Rome 
IV process.
Rationale for a Symptom-based  
Classification 
A FGID (eg, functional heartburn and IBS) relates to the 
patients’ interpretation and reporting of the illness experience, and 
it is classified primarily in terms of symptoms. A symptom is an 
experience perceived as different from normal, while a syndrome 
(eg, any of the FGID) is a consistent association of symptoms.13 
While a FGID may have an abnormal motility finding such as 
rapid intestinal transit in IBS patients with diarrhea (IBS-D)14 or 
a pathologic finding such as increased in colonic mucosal mast 
cells,15 these factors are neither sufficient nor necessary for defining 
Table 1.  The Rome IV Process
Years Level Actions
2008 Rome Foundation Board of Directors Identified key areas to acquire preliminary knowledge for the Rome IV Chap-
ter Committeest
2010-2012 Rome Foundation Board of Directors Creation of the Rome IV Editorial Board Members
Rome IV Editorial Board Members Identified Chairs and Co-chairs of the 18 committees
Rome IV Committees Chairs and Co-chairs Selection of committee members to produce Rome IV Chapters
Rome Foundation Board of Directors Creation of Support Committees to provide ancillary service to the chapter 
committees
2013 (May) Rome Foundation Board of Directors Orientation meeting
Support Committees Presented their work
2013-2015 Rome IV Committees Critically synthesized the literature and created the requested documents 
through several revisions.
2014 (December) Rome IV Committees Meeting in Rome (Rome IV Conference) to revise the documents and estab-
lished consensus on scientific content an diagnostic criteria
Rome IV Editorial Board, Committee Chairs 
and Co-Chairs
Harmonization meeting to summarize and present their committees' recom-
mendation to the group
2015 Committee Chairs and Co-Chairs Each document was sent out for peer-review by international experts
2015
(Autumn) 
Committee Chairs and Co-Chairs and Mem-
bers
Manuscripts for the Rome IV Gastroenterology supplements were created
Rome IV Editorial Board Reviewed the manuscripts for the Rome IV Gastroenterology supplements
Rome IV Committee Members Signed off on all documents before they were sent to copy editor for final check
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a FGID. Thus, by moving from motility based categorization to 
a symptom based method we can identify underlying pathophysi-
ological determinants, be they motility, hypersensitivity, or brain-
gut dysfunction. This classification based on symptom groupings 
(developed by population cluster analysis and clinical studies) thus 
represent what patients bring to doctors. This approach opens the 
door for the study of additional pathophysiological processes. It is 
not coincidence that the growth in the work on visceral hypersensi-
tivity and sensitization, brain-gut interactions, microbiota etc, began 
right at the time of the classification system published in 1990.16-19 
Because patients were selected for these studies based on symptom 
criteria which defined the cohorts. Other benefits include the ability 
of having homogeneous groups for clinical trials with the Food and 
Drug Administration (FDA) and European Medicines Agency 
endorsement of these criteria. This led to a marked increase in drug 
discovery and use.20-22 Finally such a classification system provides 
legitimization for patients and doctors.
A New Definition for Functional  
Gastrointestinal Disorders: Disorders of 
Gut-Brain Interaction 
Although the word functional has been embedded in our ter-
minology, there has been a longstanding discussion to eliminate this 
term because of the term being non-specific and potentially stigma-
tizing. Based on more recent scientific knowledge that proposes the 
interaction of multifactorial pathophysiological factors involved on 
the generation of these disorders, a revised definition was created: 
disorders of gut-brain interaction (DGBI) to help clarify its mean-
ing. These disorders are defined as a group of disorders classified 
by GI symptoms related to any combination of motility disturbanc-
es, visceral hypersensitivity, altered mucosal and immune function, 
gut microbiota, and/or central nervous system processing. We will 
be using this new term throughout the article to represent FGIDs. 
Functional has been removed from the chapters and article titles 
(for example Gastroduodenal Disorders instead of Functional Gas-
troduodenal Disorders) and from certain diagnoses when possible 
(for example Fecal Incontinence instead of Functional Fecal Incon-
tinence). The Rome Foundation understands that it will take time 
until the term functional is completely eliminated from the health care 
language, and in some clinical disorders the term functional was re-
tained to distinguish them from other similar disorders (for example 
Functional Diarrhea) until a more appropriate term can be used.13
Multicultural Orientation 
Traditionally, the Rome approach was based on Western knowl-
edge to understand patients’ symptoms, which has limitations for 
other countries and cultures.2,13 Thus, one of the major changes in 
Rome IV is addressing these limitations by moving from a Western 
ethnocentric focus to a multi-cultural orientation. This could be 
uniquely accomplished through 117 experts from 23 countries as 
part of the Rome IV process. What resulted was the inclusion of 
a new chapter devoted entirely to multi-cultural information that 
addresses the global perspective on these disorders. This chapter, 
“Multi-cultural Aspects in Functional Gastrointestinal Disorders 
(FGIDs)”23 was an extension of the Rome Foundation Working 
Team on Multinational, Cross-Cultural Research, which completed 
its work in 2014.24-26 The chapter elaborated on a conceptual model 
relating to the interaction between culture and DGBI, focusing 
on patients, physicians, food and eating, and culture in symptom 
interpretation and clinical manifestations.27 Culture defined as the 
values, beliefs, norms, and practices of a particular group that are 
learned and shared28 can guide, thinking (eg, food taboos), deci-
sions (eg, illness explanatory model), and actions (eg, treatment 
choice). Patients have symptoms or disease related beliefs that af-
fect their concerns, anxieties, and expectations of the health care 
process known as explanatory models.29 Although factors such as 
the cultural background, educational level, and sex can contribute 
to these explanatory models, we also recognize that local biologics 
including genetics, microbiome/post-infectious IBS, environmental 
hygiene, cytokines, and the effects of CNS, can impact on symptom 
generation, manifestation, and interpretation. Also considered were 
the explanatory models of illness that may impose a barrier to the 
physician-patient relationship; gender; family relationships that 
can have a significant effect on the illness experience of the patient; 
and last but not least, symptom reporting as this varies between 
groups.23,30 The most characteristic issue in terms of symptom 
reporting is bloating, a term confined primarily to the English lan-
guage but absent in Spanish or Italian.23 Also, the differentiation of 
bloating from postprandial fullness imposes a linguistic and cultural 
issue. For example, in China, postprandial fullness is limited to the 
epigastrium while bloating refers to a sensation of gas that is pres-
ent in most, if not the entirely all over the abdomen and can reflect 
abdominal discomfort. However, discomfort is another expression 
without a translation to many languages. Therefore, pictograms 
may have to be designed and validated in the future for conducting 
cross-cultural research.23,27
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As for food, in most cultures it plays a prominent role in DGBI 
patient symptom attribution and reporting and cultural factors can 
have a negative or positive meaning to food such as nocebo or pla-
cebo properties. Finally, physicians need to be prepared to work in a 
multicultural milieu to address this issues and be aware of how can 
religion and culture can affect treatment modalities including Com-
plementary and Alternative Medicine, which should be included in 
the Western type of treatments. Notwithstanding, the differences in 
healthcare systems can influence the diagnostic work-up and treat-
ment itself.27
New Chapters 
Not only the previous Rome III chapter on “Gender, age, so-
ciety, culture, and the patients perspective” was split to give rise to 
2 new Rome IV chapters, the “Multicultural Aspects in Functional 
Gastrointestinal Disorders”23 and “The Age, Gender, and Women’s 
Health,”31 and also a new chapter entitled “The Intestinal Microen-
vironment and Functional Gastrointestinal Disorders,”32 was added 
based on the increasing evidence supporting a role for luminal gut 
factors in the generation of DGBI such as IBS and functional dys-
pepsia.32 They included the interaction between diet and products 
of digestions, enteric infections or infestation, the microbe-host 
interactions including the immune and metabolic responses and 
biliary acids among others. These factors can interact with the gut 
mucosa not only triggering a leaky barrier, but in the presence of a 
permeability abnormality may allow an amplification of signaling 
from the lumen to neural and immune pathways, generating func-
tional gastrointestinal symptoms.33
The “Psychosocial Aspects of Functional Gastrointestinal 
Disorders” chapter was changed to “Biopsychosocial Aspects of 
Functional Gastrointestinal Disorders”34 to reflect the multi-deter-
mined nature of these processes. Finally the Rome III chapter on 
“Functional abdominal pain syndrome,” was changed to “Centrally 
Mediated Disorders of Gastrointestinal Pain” to reflect the range 
of gastrointestinal symptoms believed to have a central origin,35 
where central dysregulation of pain is the major contributor to the 
disorder.36 The chapter includes the “Centrally mediated abdominal 
pain syndrome (CAPS)” resulting from central sensitization with 
disinhibition of pain signals rather than increased peripheral affer-
ent excitability; and a new disorder called narcotic bowel syndrome 
(NBS) (see “New Disorders” section and “Diagnostic Criteria” 
section).36
New Disorders 
Rome IV has included new diagnoses that have a known eti-
ology, yet they are included because they fit the new definition of 
DGBI, as related to their effects on altering the function of the 
CNS or enteric nervous system, and their clinical presentation is 
similar to DGBI, and the need to be readily recognized by clini-
cians. Also, they have not been fully accepted as discrete disorders 
nor have they been well characterized yet.13 These new diagnoses 
include the NBS (Opioid-Induced Gastrointestinal Hyperalgesia) 
in the chapter, “Centrally Mediated Disorders of Gastrointestinal 
Pain”;36 Opioid Induced Constipation in the chapter, “Bowel Dis-
orders”;37 and Cannabinoid Hyperemesis Syndrome in the chapter 
“Gastroduodenal Disorders.”38
Threshold Changes: Normative Survey 
Because there was limited information on the frequency of nor-
mal bowel symptoms in the general population, the Rome Founda-
tion conducted a normative symptom study in a non-clinical sample 
in the USA, to be able to identify the prevalence of normalcy in 
order to statistically derive abnormal frequencies consistent with 
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Figure 1. Frequency of reporting of pain or burning above the belly 
button in the normative survey. The histograms show the frequency 
of reporting in different time frames for men, women and the com-
bined sample. The vertical dotted line shows the 90th percentile for 
the combined sample of females and males. MT shows the minimum 
threshold in males and FT shows the minimum 90th percentile in 
females. Accordingly, a threshold of only 2-3 days a month would 
limit misclassification to 10% in females, whereas a threshold of 1 day/
month would limit misclassification to 10% in males. Reproduced 
with permission from Rome Foundation, Inc.
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DGBI.39 The committee recommended the 90th percentile symp-
tom frequency or men and women as the threshold to define nor-
mality.39 For example, the presence of discomfort or pain anywhere 
in the abdomen was reported in the majority in the general popula-
tion less than 2-3 days per month to never, and once a week or more 
for the combined sample occurred in 6.7%. Therefore, the fre-
quency threshold for pain in IBS was set statistically at a minimum 
of once a week in Rome IV.37,39 Another example is the frequency of 
pain or burning above the umbilicus, a cardinal symptom for func-
tional dyspepsia depicted in Figure 1. The survey revealed differ-
ences in women and men. A threshold of 2-3 days a month was the 
threshold for women according to the 90th percentile, in contrast 
to 1 day a month in men. Although the frequency was less com-
mon in men than in women, in this case, it was decided to use the 
thresholds for the combined male and female sample because the 
differences were small between the 2 of them.40 Furthermore, this 
higher frequency in women probably responds to an epidemiologi-
cal phenomenon that explains why many functional gastrointestinal 
symptoms including uninvestigated dyspepsia are more frequent in 
women.41,42
Changes in Diagnostic Criteria 
The Rome IV categories and diagnoses for DGBI are listed in 
Table 2.11 In the following section, we describe the changes and new 
diagnostic criteria that have been included in Rome IV from the up-
per to the lower digestive tract. 
Esophageal Disorders
With Rome III, functional heartburn was associated with no 
evidence for gastroesophageal reflux.43 However, with the addition 
of impedance to esophageal pH monitoring it has been shown that 
38% patients did not have acid reflux (pH-), yet had a positive 
symptom association based on the symptom associated probability 
(SAP+), in other words they had esophageal hypersensitivity with 
only 29% having true functional heartburn (pH-/SAP-).44 There-
fore, a new diagnosis was included, reflux hypersensitivity, defined 
by the presence of acid sensitivity in the absence of increased acid 
reflux.45
It must be noted that reflux hypersensitivity can overlap with 
true gastroesophageal reflux disease that can be identified in patients 
with known prior pathological reflux or erosive esophagitis in which 
reflux parameters (number of reflux events and acid exposure) are 
documented to have normalized on pH-impedance testing on pro-
ton pump inhibitors.45 
Gastroduodenal Disorders 
Functional dyspepsia (FD) remains as an umbrella term refer-
ring to patients with postprandial distress syndrome (PDS) and epi-
gastric pain syndrome (EPS).38 In general, PDS is a postprandial 
syndrome while EPS is not. However, pathophysiological studies 
investigating the effect of meal ingestion on symptom generation 
demonstrated that not only postprandial fullness and early satiety 
but also, epigastric pain or burning and nausea may increase after 
meal ingestion.46 In other words, they can overlap. Therefore, the 
definition of PDS acknowledges that besides postprandial fullness 
and early satiety, patients may perceive epigastric pain and/or burn-
ing after meals.38 Also, bloating, belching, and nausea can be pres-
ent both in PDS and EPS, but vomiting is unusual. 
Secondly, in Rome III a diagnosis of FD could be made with 
no minimum frequency of occurrence required. However, based on 
the normative survey, Rome IV now require a minimum frequency 
of occurrence for the dyspeptic symptoms (ie, postprandial fullness, 
early satiation, epigastric pain, and epigastric burning) before a di-
agnosis of FD is made (see above in “Normative Survey”) (Fig. 1).
Third, other minor changes included severity identified at least 
as bothersome (severe enough to impact on daily activities).38 For 
research purposes, bothersome can be semi-quantitatively defined as 
≥ 2 (ie, severe enough to at least distracting from usual activities) in 
a 5 point-scale to the effect exerted by symptoms on usual activities. 
Chronic idiopathic nausea and functional vomiting syndrome 
were 2 separate entities in Rome III.47 However, because of the lack 
of evidence to support different diagnostic investigations and treat-
ments for these disorders, and the observation that both symptoms 
commonly coexist, Rome IV delineated a combined diagnosis called 
chronic nausea vomiting syndrome.48 Notwithstanding, it was rec-
ognized that patients may present only with nausea or vomiting.48 
Bowel Disorders
Previous versions of Rome considered functional bowel dis-
orders such as IBS, functional diarrhea, functional constipation, 
and functional distension (Rome I) as separate entities. Later it 
was recognized that these disorders could overlap (Rome II-Rome 
III). However, in the clinic it may be not be possible to confidently 
separate disorders into separate entities. Such is the case of IBS with 
predominant constipation (IBS-C) from functional constipation or 
IBS-D from functional diarrhea. Thus, Rome IV considers that 
these disorders exist as a continuum rather than as in isolation (Fig. 
2).49 Furthermore, it is recognized that bloating and/or distension 
are common symptoms frequently reported by patients with any 
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Table 2. Rome IV Classification of the Functional Gastrointestinal Disorders–Disorders of Gut-Brain Interaction
A. Esophageal disorders
A1. Functional chest pain 
A2. Functional heartburn 
A3. Reflux hypersensitivity
A4. Globus
A5. Functional dysphagia
B. Gastroduodenal disorders
B1. Functional dyspepsia 
   B1a. Postprandial distress syndrome  
   B1b. Epigastric pain syndrome  
B2. Belching disorders 
   B2a. Excessive supragastric belching 
   B2b. Excessive gastric belching
B3. Nausea and vomiting disorders
   B3a. Chronic nausea vomiting syndrome
   B3b. Cyclic vomiting syndrome 
   B3c. Cannabinoid hyperemesis syndrome 
B4. Rumination syndrome
C. Bowel disorders
C1. Irritable bowel syndrome 
   IBS with predominant constipation 
   IBS with predominant diarrhea 
   IBS with mixed bowel habits 
   IBS unclassified  
C2. Functional constipation
C3. Functional diarrhea
C4. Functional abdominal bloating/distension
C5. Unspecified functional bowel disorder
C6. Opioid-induced constipation
D. Centrally mediated disorders of gastrointestinal pain
D1. Centrally mediated abdominal pain syndrome D2. Narcotic bowel syndrome/opioid-induced gastrointestinal hyperalgesia
E. Gallbladder and sphincter of Oddi disorders
E1. Biliary pain
   E1a. Functional gallbladder disorder
   E1b. Functional biliary Sphincter of Oddi disorder
E2. Functional pancreatic sphincter of Oddi disorder
F. Anorectal disorders
F1. Fecal incontinence 
F2. Functional anorectal pain 
   F2a. Levator ani syndrome 
   F2b. Unspecified functional anorectal pain
   F2c. Proctalgia fugax
F3. Functional defecation disorders
   F3a. Inadequate defecatory propulsion
   F3b. Dyssynergic defecation
G. Childhood functional gastrointestinal disorders: neonate/toddler
G1. Infant regurgitation 
G2. Rumination syndrome 
G3. Cyclic vomiting syndrome 
G4. Infant colic
G5. Functional diarrhea
G6. Infant dyschezia
G7. Functional constipation
H. Childhood functional gastrointestinal disorders: child/adolescent
H1. Functional nausea and vomiting disorders 
   H1a. Cyclic vomiting syndrome 
   H1b. Functional nausea and functional vomiting 
      H1b1. Functional nausea 
      H1b2. Functional vomiting disorders
   H1c. Rumination syndrome 
   H1d. Aerophagia 
H2. Functional abdominal pain disorders
   H2a. Functional dyspepsia
      H2a1. Postprandial distress syndrome
      H2a2. Epigastric pain syndrome
   H2b. Irritable bowel syndrome 
   H2c. Abdominal migraine
   H2d. Functional abdominal pain - not otherwise specified
H3. Functional defecation
   H3a. Functional constipation
   H3b. Non-retentive fecal incontinence
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functional bowel disorder.49 
Irritable bowel syndrome is the most commonly recognized 
DGBI around the world, notwithstanding is prevalence remains 
elusive due to the different diagnostic criteria and survey methods 
used in research studies.50 However, Rome IV has introduced 
changes in the diagnostic criteria based on the available evidences,51 
as well as on the normative survey.39 Firstly, the term discomfort 
included in the Rome III criteria is now eliminated from the new 
Rome IV criteria because a previous study showed that  asking 
about discomfort is nonspecific and should be avoided in future 
Patient reported outcomes. Also, discomfort has different meanings 
in different languages and is an ambiguous term to patients.51 Thus, 
only abdominal pain is now included. Based on the Rome norma-
tive survey, pain should be present at least 1 day per week during 
the previous 3 months. As mentioned before, this was supported 
by the fact that according to the 90th percentile a lower frequency 
of pain was common in the general population.39,40 In addition, 
in Rome III, pain or discomfort had to improve with defecation 
although in many patients, pain increases with defecation or it re-
mains without changes.52 Also, in Rome III, pain or discomfort on-
set had to be related with the other 2 criteria: onset associated with 
a changed in frequency of stools; onset associated with a change of 
form (appearance) of stool.53 Because not in every patient abdomi-
nal pain coincided with these changes in stools, onset is now deleted 
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Figure 2. Different models to explain functional bowel/disorders of gut-brain interaction. (A) Rome I considered the functional bowel disorders 
as different and independent entities. (B) Later, Rome II-Rome III recognized that these disorders could overlap between the different functional 
bowel disorders. (C) Rome IV now considers that bowel disorders exist on a continuum rather than independent disorders. Adapted and repro-
duced from Whorwell et al35 with permission from Rome Foundation, Inc. IBS, irritable bowel syndrome; FC, functional constipation; FDr, func-
tional diarrhea; C, constipation; D, diarrhea; M, mixed. 
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Figure 3. Changes in diagnostic criteria for irritable bowel syndrome (IBS) from Rome III to Rome IV. In Rome IV abdominal ‘discomfort’ has 
been deleted from the definition because of the imprecise nature of the term together with the fact that ‘discomfort’ is not present in every lan-
guage; abdominal pain should be present at least 1 day a week on average during the preceding 3 months; ‘Improvement with’ defecation has been 
changed to ‘Related to’ defecation as in a subgroup of patients it may increase or remain without changes; and ‘Onset’ has been deleted from the 
associated changes in frequency and change in form (appearance) of stools. Adapted from Longstreth GF et al53 and Mearin F et al.49
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from Rome IV.37 The changes in IBS criteria from Rome III to 
Rome IV are depicted in Figure 3. It is important to acknowledge 
that in the first population-based study using Rome IV criteria in 
English speaking populations, the IBS prevalence decreased by half 
compared to that with Rome III criteria: 11.1% vs 6.1%, 11.7% vs 
5.8%, and 10.6% vs 5.5% in the US, Canada, and the UK, respec-
tively. It is possible that this change is related to the elimination of 
discomfort from the criteria.54 Also, it is worth mentioning that in 
other areas like in Asia, patients do differentiate between pain and 
discomfort and although expressions such as bloating posed dif-
ficulty in translatability, bloating is more common than abdominal 
pain, and patients often report relief of their fullness or bloating with 
the passage of either stool or flatus.55 Therefore, Rome IV criteria 
for IBS may need to be adapted in the future for other cultures as 
the data accumulates using these criteria. 
In terms of IBS subtypes, IBS is mainly classified according to 
the predominant bowel habit for IBS-C, IBS-D, IBS with mixed 
bowel habits, and unclassified IBS.53 In Rome IV, bowel habits 
are based on stool forms only during days with abnormal bowel 
movements (more than one-fourth: 25% of bowel movements).37 
This is in contrast to Rome III in which the 25% threshold was 
determined based on the total number of bowel movements irre-
spective of whether they were normal or not.53 In fact this led to a 
predominance of unsubtyped IBS using Rome III as it was the case 
in several epidemiological studies the USA and Latin America.56-58 
The Rome IV IBS subtypes criteria49 are depicted in Table 3. 
Functional abdominal bloating/distension is diagnosed when 
either abdominal bloating (subjective) and/or distension (objective/
visible increase in abdominal girth) predominate over other symp-
toms.49 The addition of distension also reflects the findings with 
new technologies such as abdominal plethysmography.59 Rome IV 
recognizes that patients may also report symptoms of mild abdomi-
nal pain and/or minor bowel movement abnormalities.
Opioid induced constipation (OIC) is one of the new disorders 
now included in Rome IV.49 It has a prevalence of 41% in patients 
with chronic non-cancer pain, and up to 94% of patients taking opi-
oids for cancer-related pain.60
Initial treatment of OIC is similar to that of functional con-
stipation including laxatives and lubiprostone has been approved 
by FDA for patients with OIC in patients with non-cancer pain.61 
Also, opioid receptors antagonists such as naloxone and nalbuphine 
that are centrally active, can be used but may be related with with-
drawal symptoms. Recently, peripherally acting µ-opioid antago-
nists (PAMORAs) that block the opioid receptors in the gastroin-
testinal tract but not centrally, have been developed.62 
Centrally Mediated Disorders of Gastrointestinal 
Pain
This category includes 2 disorders, centrally mediated abdomi-
nal pain syndrome, formerly in Rome III, functional abdominal 
pain syndrome, and the new narcotic bowel syndrome/opiate in-
duced hyperalgesia.36
Centrally mediated abdominal pain syndrome can be distin-
guished from other DGBI by its strong central component and 
relative independence from motility disturbance or evidence for 
visceral hypersensitivity. It results from central sensitization with 
disinhibition of pain signals rather than increased peripheral affer-
ent excitability.36 Symptom related behavior in patients with CAPS 
that can facilitate their identification include the expression of pain 
of varying intensity though verbal and nonverbal methods, urgent 
reporting of intense symptoms, minimizing a potential role for psy-
chosocial contributors, frequently seeking for health care, request for 
narcotic analgesics, focusing their attention on complete symptom 
relief, taking limited personal responsibility for self-management, 
and requesting diagnostic studies.35 CAPS is typically associated 
with psychiatric comorbidity, but there is no specific profile that can 
be used for diagnosis, and some degree of gastrointestinal dysfunc-
tion may be present.35
The management of CAPS relies on a strong patient-physician 
relationship, early incorporation of non-pharmacological therapies, 
and referral behavioral health therapies when needed.63 The later 
ones can include psychodynamic interpersonal psychotherapy, 
Table 3. Rome IV Irritable Bowel Syndrome-Subtypes Criteria
IBS Subtype Criteria
IBS-C More than one-fourth (25%) of bowel movements with Bristol Stool Scale Types 1-2 and less than one-fourth (25%) with Types 6-7.
IBS-D More than one-fourth (25%) of bowel movements with Bristol Stool Scale Types 6-7 and less than one-fourth (25%) with Types 1-2.
IBS-M More than one-fourth (25%) of bowel movements with Bristol Stool Scale Types 1-2 and more than one-fourth (25%) with Types 6-7.
IBS-U Patients meet diagnostic criteria for IBS but their bowel habits cannot be accurately categorized in any of the above subtypes.
IBS, irritable bowel syndrome; IBS-C, IBS with predominant constipation; IBS-D, IBS with predominant diarrhea; IBS-M, IBS with mixed bowel habits; IBS-U, 
unclassified IBS.
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hypnotherapy, mindfulness, and cognitive behavioral therapy. As 
for pharmacological therapies, low dose tricyclic antidepressants 
or serotonin-norepinephrine reuptake inhibitors can be used along 
with the general measurements.36 These medications are initially 
used for 4-6 weeks and doses can be increased in case of incomplete 
response for another similar period. If necessary, an augumentation 
protocol, that is a combination of 2 or more treatments usually at 
lower dosages, that act at different receptor sites or areas of the brain 
may be used to enhance the therapeutic effect.64
Narcotic bowel syndrome/opiate induced-gastrointestinal hy-
peralgesia is characterized by the paradoxical development of, or 
increases in, abdominal pain associated with continuous or increas-
ing dosages of opioids.65 NBS can occur in patients with DGBI, 
chronic organic gastrointestinal diseases, and painful malignant or 
non-malignant diseases.35
Treatment includes understanding and helping to modify the 
patients’ belief that narcotics are all that can help them; a sound 
patient-physician relationship and education of the patient about the 
treatment including opiate detoxification which provides a success 
rate of 89.7%. A detoxification protocol has been described else-
where.66
Gallbladder and Sphincter of Oddi Disorders
This category includes biliary pain, functional gallbladder 
disorder, and functional biliary sphincter of Oddi disorder.67 Bili-
ary pain can occur in the absence of recognized organic causes and 
some patients are cured by removal of the gallbladder or ablation of 
the sphincter. In terms of criteria changes for biliary pain disorder 
from Rome III to Rome IV is only in quantifying the pain. That 
is not significantly (< 20%) related to bowel movements and/or 
relieved by postural change or acid suppression. In addition, the 
occurrence of the pain should not be daily, although this is not evi-
dence based.67
The other changes that have been introduced in Rome IV are 
in relation to functional biliary sphincter of Oddi disorder. Dys-
function of the sphincter of Oddi (SOD) is commonly considered 
in patients with biliary-type pain after cholecystectomy, and has been 
traditionally classified in 3 clinical types of SOD based on manom-
etry and relief with sphincterotomy.67 However, a recent NIH study 
(EPISOD: evaluating predictors and interventions in sphincter of 
Oddi dysfunction) has shown that true sphincterotomy is no better 
than sham sphincterotomy in patients with post-cholecystectomy 
pain, so that the old concept of SOD Type III is now considered 
more like functional than biliary related, and endoscopic retrograde 
cholangiopancreatography approaches are no longer appropriate in 
that context.68 Furthermore, most patients with SOD Type I have 
organic stenosis (eg, stones, stricture, pancreatitis, and pancreatic 
tumor) rather than motility disturbance of the sphincter, and biliary 
sphincterotomy is recommended; however not in this biliary clas-
sification. Therefore, Rome IV now recommends using the term 
suspected functional biliary sphincter of Oddi disorder for patients 
with prior SOD Type II only.67
Normal amylase/lipase levels may occur in some pain epi-
sodes.67 Also, abnormal biliary manometry was added to the sup-
portive criteria as it has been shown to be a predictor of response 
to biliary sphincterotomy,69 and hepatobiliary scintigraphy was also 
included although its value is disputed.67
Anorectal Disorders
Subtle changes were made in this category for Rome IV.70 For 
Functional Fecal Incontinence, the diagnosis has been changed to 
a generic one, fecal incontinence.70 In Rome III, chronic proctalgia 
was subcategorized into levator ani syndrome, unspecified anorectal 
pain, and proctalgia fugax. Rome IV has retained these three sub-
categories but has deleted chronic proctalgia as it may include many 
other conditions.70 Also, the location of pain in proctalgia fugax has 
been revised to the rectum instead of anal canal or lower rectum.70
Regarding the functional defecation disorders, in the previous 
classification only patients with functional constipation would be 
eligible to be diagnosed with a defecatory disorder. However, be-
cause it has been recognized that patients with IBS and pelvic floor 
dysfunction can have an association with dyssynergic dysfunction,71 
and they can be treated with biofeedback irrespective of their as-
sociation with IBS,72 IBS-C have now been included in the Rome 
IV definition.70 In addition, criteria for inadequate propulsive forces 
and inappropriate contraction of the anal sphincter and/or pelvic 
floor muscles are no longer specified because they vary among dif-
ferent techniques.72-74
In patients with functional defecation disorders, the following 
subcategories apply: inadequate defecatory propulsion defined by 
inadequate propulsive forces as measured with manometry with or 
without inappropriate contraction of the anal sphincter and/or pelvic 
floor muscles; and dyssynergic defecation defined by inappropriate 
contraction of the pelvic floor as measured with anal surface electro-
myography or manometry with adequate propulsive forces during 
attempted defecation.70
Childhood Functional Gastrointestinal Disorders
In the last decade, new insights have been gained about the dif-
ferent DGBI in “neonate/toddlers” and “child/adolescents.” The 
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current criteria are based more on evidence and less on the experts’ 
experience. DGBI in “neonates and toddlers” include: infant regur-
gitation, infant rumination syndrome, cyclic vomiting syndrome, in-
fant colic, functional diarrhea, infant dyschezia, and functional con-
stipation.75 Main changes have been introduced in infant colic that 
has been expanded to include criteria for the general pediatrician 
and specific criteria for researchers. Also, a section on Neurobiology 
of Pain in infants and toddlers has been added that addresses the 
neurodevelopment of nociception and of the wide array of factors 
that may impact the experience of functional pain. This is contrary 
to the explanation of the acute pain model that if the pathology of 
pain is addressed, the pain will dissipate.75 
In the “child/adolescent” section, based on the available evi-
dence, the statement “no evidence for organic disease” has been 
removed from every definition and is now replaced for “after ap-
propriate medical evaluation the symptoms cannot be attributed 
to another medical condition.”76 Functional nausea and functional 
vomiting has now been included and in functional dyspepsia, the 
PDS and EPS subtypes which were not present in Rome III, have 
now been adopted. Also, the Rome III functional abdominal pain 
and functional abdominal pain syndrome has now been substituted 
for Functional Abdominal Pain-Not Otherwise Specified. The fre-
quency required for pain is changed from weekly to 4 times/month 
to align with other functional abdominal pain disorders (FAPD) 
and to allow for the inclusion of children who would otherwise not 
qualify for FAPD. In addition, the wording “that does not occur 
solely during physiologic events (eg, eating, menses)” has been 
added to harmonize with the adult criteria. Finally, it has been rec-
ognized that DGBI can coexist with other medical conditions such 
as inflammatory bowel disease.76
Clinical Applications and Resources: Clinical 
Algorithms, the Multidimensional Clinical 
Profile, Interactive Clinical Decision Toolkit, 
and Primary Care 
Although the Rome criteria are very useful for clinical research 
and pharmaceutical trials, they have limitations in clinical practice, 
as many of our patients do not fulfill all the criteria or the necessary 
time frame to be diagnosed (sub-threshold disorders), however they 
would receive equivalent treatments.
“The Rome IV diagnostic algorithms for common gastrointes-
tinal disorders” have been published to meet clinical standards in 
diagnostic evaluation since the publication of the previous edition 6 
years before, and to be consistent with the new Rome IV diagnostic 
criteria.77 An updated set of diagnostic approaches beginning with 
common symptoms (eg, abdominal pain, nausea, diarrhea, and con-
stipation) leading to diagnostic testing and ending with diagnosis, 
is provided. This would be the first part of the clinicians decision in 
making a diagnosis, and this would be followed by treatment.77
Furthermore, the Multidimensional Clinical Profile (MDCP) 
has been developed to capture the full dimension of each patient’s 
clinical presentation and therefore planning an individualized treat-
ment, and is also updated for Rome IV,78 The MDCP is probably 
the first attempt to a Personalized Medicine approach in the field of 
DGBI. The MDCP comprises of five categories depicted in Table 
4.78 The Rome IV MDCP book included 72 cases to enhance the 
learning about DGBI and the influence of physiological and psy-
chological factors contributing to the patients clinical presentation. 
Pediatric and multicultural cases have been included as well.79 
Rome has created the Rome IV Interactive Clinical Decision 
Toolkit, an intelligent software system that addresses the sophistica-
tion and complexity of DGBI diagnosis and treatment protocols 
Table 4. The Multidimensional Clinical Profile Categories
Categories Examples
A. Categorical diagnosis based on Rome IV criteria
B. Clinical modifiers Bowel habit predominance (ie, IBS-D, IBS-C, IBS-M), post-infection (PI), 
gluten sensitivity, FODMAPs sensitivity
C. Severity impact by self-perception Mild, moderate, severe
D. Psychosocial modifiers and comorbidities Can be categorical (eg, DSM Axis I), dimensional (eg, HADS, psychosocial 
red flags), or patient reported (eg, abuse)
E. P hysiological modifiers and biomarkers of clinical  
relevance that enhance understanding of the diagnosis
eg, motility, biochemical, antibodies
IBS-C, IBS with predominant constipation; IBS-D, IBS with predominant diarrhea; IBS-M, IBS with mixed bowel habits; FODMAPs, fermentable oligo-, di-, 
monosaccharides, and polyols; HADS, Hospital Anxiety and Depression Scale; DSM, Diagnostic and Statistical Manual of Mental Disorders.
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by providing an online resource to assist practitioners in achieving 
optimal clinical outcomes. It offers a powerful online and interactive 
approach for accessing the combination of the Rome IV Diagnostic 
Algorithms and the MDCP treatment guidelines on-demand and 
at the point of care. This software will provide both an educational 
resource as well as a daily guideline to the patients’ individualized 
diagnosis and treatment. Using any browser-enabled device, phy-
sicians and clinicians interact visually with Rome algorithms and 
guidelines, seeing all relevant decision pathways developed from 
actual clinical cases and using touch inputs to highlight and activate 
the pathways that lead to the optimal outcomes and recommenda-
tions. The platform operates in the ways that clinicians need to 
work: by using a logical, multidimensional and yet individualized 
framework for proper decision making.
Rome IV has also published “The pediatric functional gastro-
intestinal disorders” book and “The diagnostic questionnaires and 
tables for investigators and clinicians” book. Finally, recognizing 
that DGBI are ever present and disorders such as IBS are one of 
the main reasons for consultation in primary care, Rome IV has 
published a handbook to help busy primary care physicians on how 
to diagnose and managed the most common DGBI seen at this 
level of healthcare.80
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